|
Post by chang on Nov 2, 2021 17:38:28 GMT
Nice day to be a Pfizer owner.
|
|
|
Post by uncleharley on Nov 2, 2021 17:53:06 GMT
Nice day to be a Pfizer owner. Helluva bounce after a correction. My wife owns it in her account.
|
|
|
Post by bb2 on Nov 2, 2021 19:02:45 GMT
|
|
|
Post by chang on Nov 5, 2021 11:48:44 GMT
Pfizer is up again strongly in the pre-market. One of my few (and largest) individual stock holdings, which is why I am following it.
|
|
|
Post by uncleharley on Nov 5, 2021 11:54:29 GMT
They are delivering Covid shots for children. I have not read of any other Pharma that has the vaccine for kids.
|
|
|
Post by yogibearbull on Nov 5, 2021 13:21:54 GMT
There is news about Pfizer Covid-19 oral pill although Merck is ahead on this. Pros - pill interferes with Covid-19 replication, so the infection dies; cons - it may cause problems in people prone to cancer.
|
|
|
Post by anitya on Nov 23, 2021 20:01:24 GMT
It has been disconcerting that Health Care sector has been a laggard. As a example, looking at the chart for FSPHX vs FBALX from Feb 19, 2020 through now. FBALX is a total return winner with a much smoother ride. Over the past one year, FBALX has outperformed by 10%. It lagged FSPHX slightly at the beginning of the 2020 recovery only because it has less equities. FBALX also has better current momentum than FSPHX. So, I was asking myself if it is time to fold FSPHX into FBALX and thought I would ask if you guys know of any government initiatives that would give a boost to the sector just so I do not screw up the timing. E.g., ACA did great for the sector.
For reference, copied from Yogi's Sept 25 Barron's cover write up but I am not interested in biotech per se - "[W]hy have biotech ETFs IBB (market-cap weighted) and XBI (equal weighted) have lagged the SP500? Reason may be that many new companies became public and diluted some great prior successes; 54% of IPOs in 2020 and 44% of IPOs YTD have been in healthcare. There is a lot of M&A activity. Many Big Pharma are using M&A to buildup their drug pipelines. On the government side, not much has happened lately – Medicare Part D (prescriptions) was in 2003; ACA/Obamacare was in 2010. But there are lots of noises about drug pricing; drug access; generics; drug approvals, etc." [Bold added]
|
|
|
Post by chang on Nov 23, 2021 22:11:15 GMT
I’m keeping my FSPHX. The HC sector can’t lag forever, can it?
The continued outperformance of FSMEX compared to FSPHX stymies me, though. I hold both, but about 2.5 times more of FSPHX.
I always feel that I’m the last person to spot a trend, and by the time I see it it’s too late to act on it.
|
|
|
Post by jongaltiii on Nov 24, 2021 4:01:30 GMT
anitya, chang, I held FSPHX for a long time. Also own FBALX. Early this year, looked closer at FSMEX and FSPHX and FSMEX kept outperforming (1-5-10 yr) with same risk and ER. Exchanged all of FSPHX for FSMEX and haven't looked back. YTD FSMEX +22.50 FSPHX +8.42 FBALX +17.38 FXAIX +26.26 = S&P500 What is it about FSPHX that would cause you to want to hold more of it than FSMEX? While there's some overlap in top holdings, there are notable differences too like Dexcom etc.
|
|
|
Post by chang on Nov 24, 2021 6:05:52 GMT
What is it about FSPHX that would cause you to want to hold more of it than FSMEX? Simple, it’s more diversified (within the confines of a HC sector fund) and can go anywhere the manager wants - pharmas, insurance, hospital REITs, biotech, and of course equipment and technology. FSMEX is a sub-sector fund limited to the last mentioned sub-sector. I also own PFE stock, so I may be a little overweight in the sector. I probably should consider sliding some FSPHX over to FXAIX (I’ve got both in the same IRA, so this would be easy), but I hate moving money from a warm fund to a hot fund.
|
|
|
Post by chang on Nov 29, 2021 3:05:01 GMT
Amid Friday’s slaughter, Pfizer managed to add 6%. Hopefully a further bump today.
It’s one of my few individual stocks … and oddly NOT a significant holding of FSPHX.
|
|
|
Post by chang on Jan 13, 2022 3:17:35 GMT
Hopefully people will continue to update this thread with their thoughts. I am still holding HC in the form of FSPHX and FSMEX. I still don't know what to make of the slump. Biotechs have been truly awful. (I sold XBI at $110 after waiting waaaay too long, and I'm glad I did since it subsequently dropped to $100, after reaching a high of $175 last year.)
I plan to hold my HC. I just do not see how it can underperform the S&P500 forever.
|
|
|
Post by retiredat48 on Jan 13, 2022 5:53:48 GMT
I have a substantial core-type allocation/holding in healthcare...but no specific biotech fund.
Biotech is on my close watch list.
Will wait until apparent bottom...or a compelling value exists for the initial buy, and then start buying and Pyramiding Up from there!! Will also try to buy the bio fund that is moving up the fastest.
R48
|
|
|
Post by jongaltiii on Jan 13, 2022 14:41:27 GMT
Deloitte has a 2022 Healthcare Outlook report that's a worthwhile read. www2.deloitte.com/global/en/pages/life-sciences-and-healthcare/articles/global-health-care-sector-outlook.html and file below: www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-health-care-outlook-Final.pdfPage 26 speaks to the digital transformation of healthcare. That said, after reading where the health care sector needs to make improvements, one can come away with the TECH sector being the biggest beneficiary - cloud based stocks, AI, tele and video (see page 40), data analytics. Forbes echoes the same: www.forbes.com/sites/forbesbusinesscouncil/2021/12/14/the-future-of-health-three-healthcare-trends-for-2022/ Schwab says Health Care to Outperform: "the sector has many favorable long-term attributes, such as new cost-saving and care-improving advances in medical technologies, an aging global population, and a growing middle class in emerging-market economies—all of whom will demand more extensive drug treatments and medical care over time. Valuations are relatively attractive, and balance sheets in the sector are generally in good shape, increasing the possibility of higher dividend payments, share-enhancing stock buybacks, and mergers-and-acquisition (M&A) activity." www.schwab.com/resource-center/insights/content/healthcare-sector Its in my explore section and I'm staying with it for the year.
|
|
|
Post by fritzo489 on Jan 13, 2022 14:46:01 GMT
Last two links didn't work. Try cut & paste. Schwab worked. Didn't try the Forbes yet.
|
|
|
Post by jongaltiii on Jan 13, 2022 16:09:26 GMT
fritzo489 all links worked fine for me. Not sure. Added the Deloitte main page vs. file download. That could be your issue. You may not like links with file download.
|
|
|
Post by Fearchar on Jan 13, 2022 17:41:12 GMT
I monitor a number of ETFs including XLV (Health Care Select Sector SPDR) and IXJ (iShares Global Healthcare).
XLV is classified as large value. IXJ is classified as large core.
XLV has an edge from a valuation perspective. Momentum is also currently favoring XLV.
While I am purposefully overweighting value, there are other stronger value funds with better momentum. Of course momentum can come and go.
|
|
|
Post by Fearchar on Jan 13, 2022 17:44:58 GMT
yikes!!
XBI is really getting slaughtered.
Like any good vulture, will be adding it to my monitoring population.
Update: XBI has taken the cake.... momentum rank at bottom and thus below ARKK.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 13, 2022 19:03:21 GMT
I have FSMEX (Fidelity Select Medical Technology and Devices) and I am continuing with it.
My 401k has started offering VHGAX (Vanguard Health Care Fund Admiral) from this year. What do you think? Is it worth considering and investing?
|
|
|
Post by roi2020 on Jan 14, 2022 4:04:36 GMT
I have FSMEX (Fidelity Select Medical Technology and Devices) and I am continuing with it. My 401k has started offering VHGAX (Vanguard Health Care Fund Admiral) from this year. What do you think? Is it worth considering and investing? I haven't looked closely at VGHAX in a while. IIRC, the fund performed well under Edward Owens. It's performance has been mediocre during Jean Hynes' tenure. Ms. Hynes is the only named manager for VGHAX and she also became Wellington CEO in 2020. It seems like she has a lot on her plate...
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 14, 2022 13:38:46 GMT
FSPHX is now in a correction, just YTD. I agree with Chang, healthcare should outperform long-term. Seems like an appropriate investment for an HSA, so I bought a fair bit yesterday.
|
|
|
Post by Chahta on Jan 14, 2022 14:03:04 GMT
FSPHX is now in a correction, just YTD. I agree with Chang, healthcare should outperform long-term. Seems like an appropriate investment for an HSA, so I bought a fair bit yesterday. I am not so sure how rosy the future is. With the threat of single payer MC looming who knows?
|
|
|
Post by FD1000 on Jan 14, 2022 14:13:01 GMT
Why would I want to own VGHAX? For several years already, I read that EM, international and Value should outperform. Never invest based on predictions and always follow markets/the money. A one year chart of VGHAX+VFIAX(SP500)+VOOV shows VGHAX lags. A one month shows that VOOV is leading easily. Why do I want to invest in one category? If I want to own another category, why not go for a unique diversifier, think VCMDX(VG commodity) OR...for many years High-Tech. How much effort it takes to get the next customer/transaction and why high-tech will continue to rule. KISS...sorry for the broken record.Attachments:
|
|
|
Post by yogibearbull on Jan 14, 2022 14:24:56 GMT
There was a piece in Barron's last week on how bad the biotechs were in 2021 and then a terrible start in 2022. It also mentioned that biotechs haven't had 2 down years in a row for a long time, so this may be a year of rebound (after some pain). I haven't checked the history, so do your own due diligence. stockcharts.com/h-sc/ui?s=XBI&p=D&yr=1&mn=0&dy=0&id=p08748128336
|
|
|
Post by anitya on Jan 14, 2022 18:24:06 GMT
A lot of active HC funds did poorly. VHT was better but still painful throughout the pandemic. XLV was the best of those I follow and was not that bad. I think it might require looking under the hood.
|
|
|
Post by FD1000 on Jan 14, 2022 22:52:30 GMT
Why HC? What is the advantage that HC has? Let's look at VHT at Vanguard ( link). 30 day SEC yield = 1.1% is low PE = 24.4 is not cheap VOO(SP500) + VOOV(Value)30 day SEC yield = 1.2 + 1.8 higher than VHT PE = 24.4 + 17.6 (SP500 equal, but Value is lower) VHT top companies: VHT earning growth=14.6UnitedHealth Group Inc. Johnson & Johnson Pfizer Inc. Thermo Fisher Scientific Inc. Abbott Laboratories Danaher Corp. AbbVie Inc. Eli Lilly & Co. Merck & Co. Inc. Medtronic plc VOO top companies. VOO earning growth=20.1Apple Inc. Microsoft Corp. Alphabet Inc. Amazon.com Inc. Tesla Inc. NVIDIA Corp. Meta Platforms Inc. Berkshire Hathaway Inc. JPMorgan Chase & Co. Home Depot Inc. Who would like to own in the next 10 years? I would still go with VOO=SP500
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 15, 2022 1:17:14 GMT
FSPHX is now in a correction, just YTD. I agree with Chang, healthcare should outperform long-term. Seems like an appropriate investment for an HSA, so I bought a fair bit yesterday. I am not so sure how rosy the future is. With the threat of single payer MC looming who knows? When people say " should outperform long-term", it worries me. I recall watching Bruce Berkowitz like 10 years back when he was still a rockstar of MF world claiming - "Every one is getting old. It is time to be in healthcare. Ignore the crowd." I do not think it worked out too well for him and his investors.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 16, 2022 14:09:34 GMT
I don't know what healthcare firms Berkowitz invested in, but I suspect Fairholme investors were hurt more by the fund's concentrated bets in, e.g., Fannie/Freddie and Sears. I agree that our healthcare system may evolve (I hope it does - our current system is terrible), but I do believe if healthcare firms aren't rewarded for drug discovery and other innovations, then we're all in trouble. According to the latest Kiplinger, FSPHX (a fund pick), has matched the S&P 500 over five years and beaten it over ten. It works well as an HSA investment: if the fund does poorly because my cost of healthcare suddenly drops, then I'm still OK. (f the fund suffers while my cost explodes - that'd be awkward.)
|
|
|
Post by johntaylor on Jan 16, 2022 15:43:44 GMT
TR Health Sci - 9% YTD, Fidelity Select Heath Care - 10% YTD
|
|
|
Post by roi2020 on Jan 16, 2022 20:13:09 GMT
FSPHX, not FLPSX. I don't know how to edit posts. @skip,
There should be an Edit button in the top-right corner of your posts.
|
|